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Abstract
Background: To evaluate fluorescence cystoscopy with hexaminolevulinate (HAL) in the early detection of
dysplasia (DYS) and carcinoma in situ (CIS) in select high risk patients.
Methods: We selected 30 consecutive bladder cancer patients at high risk for progression. After endoscopic
resection, all patients received (a) induction BCG schedule when needed, and (b) white light and fluorescence
cystoscopy after 3 months. HAL at doses of 85 mg (GE Healthcare, Buckinghamshire, United Kingdom) dissolved in
50 ml of solvent to obtain an 8 mmol/L solution was instilled intravesically with a 12 Fr catheter into an empty
bladder and left for 90 minutes. The solution was freshly prepared immediately before instillation. Cystoscopy was
performed within 120 minutes of bladder emptying. Standard and fluorescence cystoscopy was performed using a
double light system (Combilight PDD light source 5133, Wolf, Germany) which allowed an inspection under both
white and blue light.
Results: The overall incidence was 43.3% dysplasia, 23.3% CIS, and 13.3% superficial transitional cell cancer. In 21
patients, HAL cystoscopy was positive with one or more fluorescent flat lesions. Of the positive cases, there were
4 CIS, 10 DYS, 2 association of CIS and DYS, 4 well-differentiated non-infiltrating bladder cancers, and 1 chronic
cystitis. In 9 patients with negative HAL results, random biopsies showed 1 CIS and 1 DYS. HAL cystoscopy showed
90.1% sensitivity and 87.5% specificity with 95.2% positive predictive value and 77.8% negative predictive value.
Conclusion: Photodynamic diagnosis should be considered a very important tool in the diagnosis of potentially
evolving flat lesions on the bladder mucosa such as DYS and CIS. Moreover, detection of dysplasic lesions that are
considered precursors of CIS may play an important role in preventing disease progression. In our opinion, HAL
cystoscopy should be recommended in the early follow-up of high risk patients.
Introduction
Bladder cancer is costly in both human and societal
terms, yet the level of awareness of the disease and its
early symptoms is low among the public and health care
professionals. There is also a poor understanding of the
potential causative role played by exposure to workplace
carcinogens [1].
Transitional cells cancer is the most common bladder
neoplasm and his infiltrating form may heavily affect the
patient survival. In this regard the main challenge is to
early diagnose aggressive cancer yet in a limited stage or
better while it has not became infiltrating. A part of
superficial bladder cancers indeed may recur even sev-
eral times after primary resection without showing any
worsening in their malignant potential. In some cases
they come through the lamina propria, the deep submu-
cosa and muscular wall showing a clear infiltrating
course. Unfortunately the biological reasons of this radi-
cal changing of tumor behaviour are not well under-
stood. However, the presence of non-papillary
carcinoma in situ (CIS) is really considered a source of
invasive bladder cancer [2]. Furthermore, it has been
documented that even in patients with papillary disease,
most invasive cancers develop from adjacent areas of
carcinoma in situ [3]. However, in order to modify the
natural history of bladder cancer an earlier diagnosis
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might be done by identification of a known precursor of
CIS called severe dysplasia (DYS) [4,5]. Dysplasia is
often located in normal-appearing bladder mucosa and
can be easily missed under standard white-light (WL)
cystoscopy [6]. Voided-urine cytology has proven useful
as a non-invasive adjunct in the detection of CIS,
although its sensitivity in the detection of DYS may be
questionable [7,8].
Several investigators have used photodynamic agents
to detect dysplastic urothelium [9,10]. Zaak et al pre-
viously concluded that 5-aminolevulinic acid (5-ALA)
provided the most efficient diagnostic agent for patients
with flat, high-risk urothelial lesions (CIS and DYS)
compared with WL cystoscopy and cytology [11]. In our
study, we used a recently introduced, more lipophylic
ester of 5-ALA, hexaminolevulinate (HAL) to study DYS
and CIS, and compared the detection rate with this
agent to that of classic WL cystoscopy and fluorescence
cystoscopy in select high risk patients.
Materials and methods
Between March 2007 and February 2008, 30 consecutive
bladder cancer patients at high risk for progression were
selected. Patients if needed started a BCG induction sche-
dule within 30 days (once weekly for 6 weeks). The fol-
lowing WL and HAL cystoscopy control was performed
after 3 months in order to minimize the likelihood of
false positives [12,13]. Patients with porphyria, gross
haematuria, acute urinary tract infection, multi-drug
allergies, and women not on adequate contraceptive mea-
sures or who were breast feeding were excluded [14].
HAL at doses of 85 mg (GE Healthcare, Buckingham-
shire, United Kingdom) dissolved in 50 ml of solvent to
obtain an 8 mmol/L solution was instilled intravesically
with a 12 Fr catheter into an empty bladder and left for
90 minutes. The solution was freshly prepared immedi-
ately before instillation. Cystoscopy was performed
within 120 minutes of bladder emptying as described
below.
The surface of the bladder absorbs the HAL solution
and converts it to the endogenous pigment, protopor-
phyrin IX. This pigment is selectively deposited in the
tumour and causes fluorescence in the red-range when
excited by blue-violet light. The comparison of HAL
with standard cystoscopy was performed using a within-
patient design by inspecting the bladder under WL first,
followed by blue light (fluorescence). Because cystoscopy
was combined with the immediate resection of suspi-
cious lesions, all patients received sedation or spinal
anaesthesia. Before endoscopic inspection, the bladder
was evacuated. Standard and fluorescence cystoscopy
was performed using a double light system (Combilight
PDD light source 5133, Wolf, Germany) which allowed
an inspection under both white and blue light.
The purpose of preliminary WL cystoscopy was to
identify and note any exophytic lesions and suspicious
areas in the bladder chart. Subsequently, under blue
light cystoscopy, we aimed to determine the number
and location of all fluorescing areas on the same bladder
chart. In patients without suspicion, 5 random biopsies
were taken from normal appearing urothelium.
All biopsies and resected materials were analyzed by a
single pathologist blinded to the fluorescence cystoscopy
results. Lesions were staged and graded according to the
2004 WHO classification [15].
Safety assessments, including physical examinations,
vital signs, and blood sampling for hematology and bio-
chemistry were performed at baseline and again 24
hours after HAL instillation. All spontaneously reported
and observed adverse events were documented during
the hospital stay. Patients were followed for roughly 10
days until the consultation of their histologic results and
were interviewed for any adverse effects after hospital
discharge.
Categorical data were examined by chi-square test,
while continuous variables were evaluated by the t-test.
Specificity, sensitivity, positive predictive value (PPV),
and negative predictive value (NPV) were calculated
with the usual mathematical formulas.
Results
Of the 30 patients, 24 were males and 6 were females.
Their mean age was 67 (SD, 7.8; range, 46-76) years.
For 11 patients, high risk transitional cancer was the
first episode while in the remaining patients high risk
episode was recurrent. (range, 2-11 resections; average
2.8 resections). In all patients, WL cystoscopy was nega-
tive. Urinary cytology was positive in 9 patients and sus-
pected in 4 cases.
The overall incidence of DYS was 43.3% (13/30), CIS
was 23.3% (7/30), and superficial transitional cell cancer
was 13.3% (4/30). Disease-free follow-up occurred in
26.7% (8/30) of patients. In 21 patients, the HAL cysto-
scopy was positive, with one or more fluorescing flat
lesions present (mean ± SD, 2.7 ± 1.4; range 1-5). The
positive cases consisted of 4 CIS, 10 DYS, and 2 associa-
tions of CIS and DYS, well-differentiated superficial blad-
der cancer non-infiltrating to the lamina propria in 4
cases, and chronic cystitis in 1 case. In 9 patients with
negative results by HAL, the 6 random biopsies showed
one case each of CIS and DYS. HAL cystoscopy showed
90.1% sensitivity (95% CI, 0.53-0.87) and 87.5% specificity
(95% CI, 0.47-0.99) and 95.2% PPV (95% CI, 0.74-0.99)
and 77.8 NPV (95% CI, 0.40-0.96). CIS and DYS were
both visible as a brilliant-red, well-limited fluorescence
area in contrast with the normal adjacent urothelium.
HAL fluorescence cystoscopy was well tolerated and
no unexpected events were reported.
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Discussion
Bladder cancer risk categories are based on clinical and
histopathologic parameters such as number of tumours,
tumour size, prior recurrence rate, T category, presence
of concomitant CIS, and tumour grade [16,17]. Among
these, CIS is considered an important risk factor for dis-
ease progression because specific survival is heavily
affected by the presence of CIS alone or associated with
papillary superficial bladder cancer and non papillary T1
tumours [18]. So it should be necessary an earlier diag-
nosis when mucosal changes are still precursor of CIS.
DYS is considered an epithelial abnormality appearing
as a flat lesion on the bladder mucosa and a precursor
of CIS [19]. This premalignant lesion might have impor-
tant implications in the early diagnosis of bladder cancer
progression. Several recent studies have shown that con-
comitant or single DYS is associated with a considerable
risk for disease progression [20-22]. However, diagnosis
is very difficult because, in the early stages, both lesions
are indistinguishable from the normal-appearing bladder
mucosa [6] and urine cytology testing might not be suf-
ficiently sensitive [23].
The situation can be significantly improved with the
use of photo sensitizers, e.g. 5-ALA or HAL, which can
be safely administered intravesically and make these flat
lesions visible within an otherwise normal bladder
mucosa. Our results confirm the advantage in the diag-
nosis of potentially evolving flat lesions (DYS and CIS)
on the bladder mucosa examined by photodynamic,
rather than classic WL, cystoscopy. A real benefit was
shown in the diagnosis of early papillary superficial
bladder tumours that were not yet visible, confirming
previous observations [24-28].
Regarding dysplasia, in a previous study, Zaak et al.
concluded that photodynamic diagnosis using 5-ALA
was an efficient diagnostic technique for patients with
flat, high-risk urothelial lesions compared with classic
WL cystoscopy and cytology [11]. In our study, we used
HAL, a potent ester of aminolevulinic acid, that provides
better selectivity, brighter fluorescence, and requires a
shorter instillation time [29,30].
Another point of discussion is the incidence of DYS
and CIS, which was 43.3% and 23.3%, respectively, in
our study. This means that 66.6% of our patients had a
potential evolving flat lesion. In the absence of photody-
namic diagnosis, the incidence of such lesions would
have been only 6.7%. These results suggest the careful
consideration of all therapeutic possibilities, beginning
with the careful endoscopic resection, as well as the
therapeutic effect of immunoprophylaxis in these high
risk patients. Because bladder cancer is often multi-
centric, particularly when it is of high grade, a standard
WL resection might miss invisible tumours. Moreover, a
BCG induction schedule might be not sufficient to treat
these lesions making treated indeed during maintenance
schedule. However, the detection rate of these otherwise
undiagnosed lesions is higher with photodynamic
screening.
The limitations of this study are the small number of
patients included. However, we feel that this limitation
is balanced by the highly selected series.
Further studies are needed to determine whether this
important and not inexpensive diagnostic tool must be
reserved for primary or secondary look resections of
high risk patients and if the improvement in the rate of
detection of flat lesions in the follow-up may improve
the use of additional treatment and the prognosis of
these patients.
Conclusions
Photodynamic diagnosis should be considered a very
important tool in the diagnosis of potentially evolving
flat lesions on the bladder mucosa such as DYS and
CIS. Moreover, detection of dysplasic lesions that are
considered precursors of CIS may play an important
role in preventing disease progression. In our opinion,
HAL cystoscopy should be recommended in the early
follow-up of high risk patients.
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